Table of Contents

  1. Executive Summary
  2. Share Prices
  3. Companies
  1. GlaxoSmithKline
  2. Bsky
  3. Ladbrokes
  4. Whetherspoons
  5. TESCO
  1. The FTSE 100
  2. Revision of the Portfolio
  3. The future – 2008 and 2009
  4. Appendices

  1. Executive summary

        This report is based on the share performance of the companies Tesco, BSkyB, GlaxoSmithKline, Ladbrokes and Whetherspoons from 02 February to the 02 May 2008.

        Overall the share performance was fairly steady with GlaxoSmithKline, and BSKb remaining stable, Tesco performed well with Ladbroke and JD Wetherspoon not doing as well as hoped.

        When comparing our organisations with the FTSE 100 most took a similar route with only Ladbroke being up on the FTSE by the 1st May.  JD Wetherspoon was the worst performing against the FTSE being a full 17 points behind by the 1st of May.

        If asked to invest the same amount again we would consider varying our portfolio with a mix of low and high risk companies.  The group would also do more research into a wider range of companies and take in to account external issues affecting particular markets.

        The immediate future looks stable for the market, however with increases in interest rates and inflation not stable, it is possible that problems may occur in the longer term.  

   

  1. Share prices

        A sum of £ 49.999,87 has been disposed between the shares of five companies on the 2nd February 2008.  Appendix 1 shows the number of shares purchased and a calculation of brokerage fee and VAT. The below figures shows the prices of the shares maintained every Friday between the start date till the 2nd May 2008.  (All information on share prices is from the Financial Times).

        

Our portfolio consists of the following companies:

  1. Tesco;
  2. GlaxoSmithKline;
  3. BSkyB;
  4. Ladbrokes;
  5. Whether Spoons.

All the shares from below table came from  web site:

                

        As u can see from the graph below almost all companies in the global market experienced sudden falls in their share prices beginning March due to turbulence and negative speculations from the housing market in the USA and its mortgage lending together with a stronger Yen. All created doubt about the global trade. (Financial Times, 2008 a)  All companies in our portfolio were affected by this, some more than others.

  1. Companies
  1. GlaxoSmithKline

  1. The Pharmaceutical Industry
  1. The modern pharmaceutical industry is a highly competitive and profitable. Key note goes saying that: “This industry [pharmaceutical] is one of the most dynamic and successful business sectors in the UK, with a healthy trade surplus and some of the largest and most successful participants on a global scale, in spite of its relatively small size”.

  1. GlaxoSmithKline Ord Shs:

  1. Industry : Drugs
  2. Employees : 101,802
  3. Exchange : London

  1. GlaxoSmithKline:
  1. The December 2000 merger of GlaxoWellcome and SmithKline Beecham created the GlaxoSmithKline, the world's second largest pharmaceutical company with a global market share of 7%. [1]
  2. GlaxoSmithKline plc (GSK) is a global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. [2]

[1]GlaxoSmith Kline annual report (22- Feb. - 08)

[2] GlaxoSmith Kline annual report (22- Feb. - 08)

  1. Share Performance- Share prices in the sector haven’t performed well, so to ensure that GSK remain an industry leader, GSK are addressing the issues which face the pharmaceutical sector:
  • A 10% increase in the dividend paid to our shareholders for 2007.
  • The largest share buy-back programme in the industry.

  1. Price Share Graph
  • The below graph shows the price share performance over 3 months period (February, march and April) for GlaxoSmithKline company:

Source: http://markets.ft.com 

  1. Why the price shares change?

According to Thomson Financial - Shares of Hi Tech Pharmacal Co. rallied Wednesday (February) after the Amityville, N.Y.-based generic drug manufacturer said: “[t]he Food and Drug Administration has granted final approval to the company's abbreviated new drug application for fluticasone propionate nasal spray, a generic version of GlaxoSmithKline's Flonase”.

In March there was news about a drug that was making depressed teenagers more likely to commit suicide. Apart from that, was tipped on them riding low for a while, but then everything is pretty much riding low.

According to Thomson Financial: “GlaxoSmithKline PLC said Tykerb, an oral treatment for breast cancer. The Commission's decision comes after GSK released more safety data from clinical trials and a post-marketing review” in addition, within the some month GlaxoSmithKline said: “[t]he Food and Drug         Administration has approved [ours] Advair Diskus 250/50 for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. According to Katherine Hunt (LSE.com- 9 of May): “COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both [and] with this approval, Advair becomes the only treatment the FDA has approved to reduce COPD exacerbations and improve lung function”. All of this help increased the GlaxoSmithKline price shares.

Join now!

It looks like the GlaxoSmithKline price shares are going to be up next month since according to MUMBAI (Thomson Financial) - India's GlaxoSmithKline Pharmaceuticals Ltd. said it signed a licensing agreement with Japanese pharma Astellas Pharma Inc., which will give it exclusive rights to Astellas's injectible anti-fungal agent, Micafungin, in India (Source,http://markets.ft.com/tearsheets/performance.asp?s=GSK%3ALSE)

  1. BSkyB

        Satellite broadcaster BSkyB, part of Rupert Murdoch’s media empire, runs the UK’s largest digital TV platform Sky.  Majority of its revenues are generated from its subscribers, while other revenue streams include advertising and interactive services.  Recently, it has also decided ...

This is a preview of the whole essay